BioSpace News Archive

Novocure announced that Todd Longsworth, General Counsel, has resigned. Mr. Longsworth’s last day as General Counsel will be March 31.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2021 and provided a summary of recent business highlights.

Cellectis announced that it will report its financial results for the fourth quarter and year-end 2021 ending December 31, 2021, on Thursday, March 3, 2022, after the close of the US market.

Silverback Therapeutics, Inc. announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022.

Centene Corporation announced that its Board of Directors approved a request from Michael Neidorff, Chairman & Chief Executive Officer, for a medical leave of absence.

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Stephen Sands to its Board of Directors, to serve as a Class I director, effective as of February 22, 2022.

Baudax Bio, Inc. announced it has commenced a proposed underwritten public offering of shares of common stock, together with warrants to purchase its shares of common stock.

Acorda Therapeutics, Inc. will host a webcast/conference call in conjunction with its fourth quarter and year end 2021 update and financial results on Wednesday, March 9 at 4:30 p.m. ET.

Extendicare Inc. reported results for the three and twelve months ended December 31, 2021.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that, following a positive independent Data Safety Monitoring Board (DSMB) safety review, enrollment has commenced in a Phase 2a trial of PLN-74809 at 320 mg dosed once daily for at least six months in patients with idiopathic pulmonary fibrosis (IPF).